Pharmaceutical composition for prevention, treatment or delay of Alzheimer's disease or dementia containing G protein-coupled receptor 19 agent as active ingredient
The present invention relates to a pharmaceutical composition for preventing, treating or delaying an Alzheimer's disease (AD) or dementia including a G protein-coupled receptor19 (GPCR19) agonist or its pharmaceutically acceptable salt as an active ingredient and a food composition for preventing, treating or delaying an Alzheimer's disease or dementia. The GPCR19 agonist according to the present invention has an effect of improving cognitive and behavioral disorders without harming the health of objects when administrated to the objects and has an effect of preventing the Alzheimer's disease or dementia or delaying or treating the progression of the disease in the objects with the disease by suppressing apoptosis of the brain tissue, enhancing immunity, and reducing formation of an amyloid β (Aβ) plague.
1. A method for treating Alzheimer's-related disease or dementia-related disease selected from the group consisting of cerebral amyloid angiopathy, cognitive impairment, mild cognitive impairment, Alzheimer's disease-related attention deficit symptoms, Alzheimer's disease-related neural degeneration, degenerative dementia, senile dementia, cerebral vascular dementia, alcoholic dementia, parkinson's disease-related dementia, tic disorder, and corticobasal ganglionic degeneration, the method comprising administering a pharmaceutical composition containing a pharmaceutically effective amount of G protein-coupled receptor19 (GPCR19) agonist or a pharmaceutically acceptable salt thereof as an active ingredient to an individual having the disease, wherein the GPCR19 agonist is sodium taurodeoxycholate.
2. The method for treating Alzheimer's-related disease or dementia-related disease according to claim 1 , wherein the pharmaceutical composition is formulated in the form of oral, rectal, intravenous, intramuscular, intraperitoneal, subcutaneous, intranasal, or percutaneous formulation.
3. The method for treating Alzheimer's-related disease or dementia-related disease according to claim 1 , wherein the GPCR19 agonist or its pharmaceutically acceptable salt is administrated with a dose of 0.1 mg/kg/day to 1000 mg/kg/day.
4. The method for treating Alzheimer's-related disease or dementia-related disease according to claim 1 , wherein the GPCR19 agonist or its pharmaceutically acceptable salt is administrated with a dose of 1 mg/kg/day to 500 mg/kg/day.
5. The method for treating Alzheimer's-related disease or dementia-related disease according to claim 1 , wherein the GPCR19 agonist or its pharmaceutically acceptable salt is administrated with a dose of 10 mg/kg/day to 100 mg/kg/day.
6. The method for treating Alzheimer' s disease or dementia according to claim 1 , wherein the GPCR19 agonist or its pharmaceutically acceptable salt is administrated 1 to 3 times per week.